FAS deficiency is a genetic problem in the “self-destruct” pathway of immune cells. In healthy people, activated lymphocytes (a kind of white blood cell) are removed after their job is done by a safety switch called FAS (also called CD95, gene name TNFRSF6). When FAS is faulty, these cells do not die on time. They collect in the body, causing big lymph nodes, large spleen and liver, and autoimmune attacks on the blood (anemia, low platelets, low neutrophils). Doctors call this condition Autoimmune Lymphoproliferative Syndrome (ALPS); the classic form from FAS mutations is sometimes called Canale–Smith syndrome. Over time, people can also have a higher risk of lymphoma, so lifelong follow-up is important. PMC+3NCBI+3NIAID+3

FAS deficiency, also called ALPS-FAS or Autoimmune Lymphoproliferative Syndrome due to FAS mutations, is a rare genetic immune system disorder where a “self-destruct” signal on white blood cells (the Fas or CD95 receptor) does not work properly. Because abnormal immune cells don’t die when they should, they build up in lymph nodes, spleen, and liver (called lymphoproliferation). Many people develop autoimmune cytopenias (low red cells, platelets, or neutrophils because the immune system attacks them). Children often present with painless, long-lasting swollen lymph nodes and enlarged spleen. People with ALPS-FAS also have a higher lifelong risk of lymphoma. Diagnosis often includes finding increased double-negative T cells (TCRαβ⁺ CD4⁻ CD8⁻) and identifying a FAS gene mutation. NCBI+2MedlinePlus+2

On the molecular level, the FAS receptor sits on immune cells and, when bound by FAS ligand, forms a “death-inducing signaling complex” with FADD, caspase-8 and caspase-10. This turns on apoptosis (programmed cell death). Faults anywhere in this chain—most commonly in FAS—block apoptosis, leaving too many long-lived immune cells in lymph nodes, spleen, liver, and blood. NCBI

A key lab clue is very high vitamin B12 levels in blood in many people with ALPS-FAS, plus elevated IL-10, IL-18, and soluble FAS ligand (sFASL). A distinctive cell marker is an increase of “double-negative T cells” (DNTs)—T-cells that are TCRαβ-positive but CD4-negative and CD8-negative. These clues support the diagnosis along with genetic testing. NIAID+2PMC+2

Other names

• Autoimmune Lymphoproliferative Syndrome (ALPS)

• ALPS-FAS (germline FAS mutation)

• ALPS-sFAS (somatic FAS mutation)

• Canale–Smith syndrome

• TNFRSF6-related ALPS

• Historical subtypes: ALPS type Ia (FAS), Ib (FASLG), Ic (CASP10) in older literature. ASH Publications+2New England Journal of Medicine+2

Types

1. ALPS-FAS (germline FAS mutation). This is the most common form. People inherit a mutation in TNFRSF6; some variants act as dominant-negative changes in the FAS “death domain,” while others cause haploinsufficiency. Penetrance is incomplete, meaning not everyone with a mutation gets sick. NCBI+1

2. ALPS-sFAS (somatic FAS mutation). The mutation is not inherited but arises in a subset of immune cells. Patients look very similar clinically to ALPS-FAS. New England Journal of Medicine

3. ALPS-FASLG (FAS ligand mutation). Rare defects in FASLG impair signaling to FAS. NCBI

4. ALPS-CASP10 (caspase-10 mutation) and ALPS-CASP8 (rare)—defects in downstream enzymes of the death pathway. NCBI

5. ALPS-U (undetermined)—patients meet clinical/biomarker criteria but no mutation is found with current testing. ASH Publications

Note: Disorders that mimic ALPS (sometimes called “ALPS-like”) include conditions with NRAS/KRAS, PIK3CD, STAT3, or CTLA4 variants; these share autoimmunity/lymphoproliferation but are not classic FAS deficiency. MedlinePlus

Causes

Primary (genetic) causes

1. Germline TNFRSF6 (FAS) missense variants affecting the death domain—often dominant-negative. NCBI

2. Germline FAS haploinsufficiency (nonsense/frameshift/large deletion), reducing FAS amount on cells. NCBI

3. Somatic TNFRSF6 mutation restricted to lymphocytes (ALPS-sFAS). New England Journal of Medicine

4. Germline FASLG mutations (defective ligand). NCBI

5. Germline CASP10 mutations. NCBI

6. Rare CASP8 mutations affecting extrinsic apoptosis. NCBI

Variant-level mechanisms

7. Splice-site mutations disrupting FAS isoforms and signaling. NCBI

8. Promoter/regulatory variants lowering FAS expression on lymphocytes. NCBI

9. Compound heterozygosity or recessive FAS defects (uncommon but reported). NCBI

Conditions that can look similar (ALPS “phenocopies”)—important in work-up

10. NRAS/KRAS (RALD) mutations causing ALPS-like features. MedlinePlus

11. PIK3CD (activated PI3K-δ syndrome) with lymphoproliferation and autoimmunity. MedlinePlus

12. STAT3 gain-of-function disease with cytopenias/adenopathy. MedlinePlus

13. CTLA4 insufficiency or other immune checkpoint defects. MedlinePlus

14. MAGT1 deficiency (XMEN) with chronic EBV and adenopathy. MedlinePlus

Triggers/worseners for flares in people who already have FAS pathway defects

15. Intercurrent viral infections (e.g., EBV, CMV) can precipitate lymph node swelling or autoimmune cytopenias. PMC

16. Immune activation after vaccinations or illnesses (rarely noted as temporal associations in case series; clinicians evaluate case-by-case). PMC

17. Medication-induced immune activation (general principle in autoimmunity; clinicians review recent drugs during flares). PMC

18. Hormonal and growth phases (childhood/adolescence) when ALPS often first shows. NIAID

19. Coexisting autoimmune disease that amplifies immune activation. PMC

20. Family-specific genetic modifiers (penetrance of FAS variants is <60%; other genes/life events influence who becomes ill and when). PMC

Common symptoms and signs

1. Enlarged lymph nodes that are painless and long-lasting in neck, armpits, or groin. This is due to too many long-lived lymphocytes. NIAID+1

2. Big spleen (splenomegaly)—fullness or discomfort on the left side, sometimes low platelets from spleen pooling. NIAID

3. Big liver (hepatomegaly)—a feeling of heaviness under the right ribs. NIAID

4. Autoimmune hemolytic anemia—pallor, fatigue, yellow eyes/skin (jaundice), dark urine. NCBI

5. Autoimmune thrombocytopenia—easy bruising, nosebleeds, gum bleeding. NCBI

6. Autoimmune neutropenia—recurrent infections (mouth sores, skin or respiratory infections). NCBI

7. Fevers not explained by a clear infection, reflecting inflammation. NIAID

8. Fatigue and reduced exercise tolerance (from anemia or chronic inflammation). PMC

9. Night sweats or weight loss during active disease; doctors also rule out lymphoma. NCBI

10. Rash or hives from autoimmune activity. PMC

11. Enlarged tonsils or adenoids due to lymphoid overgrowth. NCBI

12. Autoimmune hepatitis (liver inflammation) or nephritis (kidney). NCBI

13. Hypergammaglobulinemia (high IgG/IgA) on lab testing; sometimes causes thicker blood proteins but is mainly a diagnostic clue. New England Journal of Medicine

14. High vitamin B12 levels on routine labs—surprisingly common in ALPS-FAS and useful as a biomarker. NIAID+1

15. Increased lifetime risk of lymphoma, especially Hodgkin and non-Hodgkin types—so any new, hard, rapidly growing nodes need medical review. MedlinePlus

Diagnostic tests

A) Physical examination (how the doctor looks and feels for clues)

1. Head-to-toe lymph node exam. Doctors check size, number, and tenderness; ALPS nodes are usually multiple, mobile, and non-tender, lasting >3 months. NIAID+1

2. Spleen and liver palpation. Feeling for enlargement helps stage disease activity and watch for risk from trauma with big spleens. NIAID

3. Skin and mucosa check. Bruises, petechiae, gum bleeding (platelets), pallor/jaundice (anemia), mouth ulcers (neutropenia). NCBI

4. Growth and nutrition review in children. Chronic inflammation and cytopenias can affect growth and energy. NIAID

B) Manual bedside tests / simple office studies

5. Vital signs and fever diary. Tracks inflammatory activity and secondary infections during flares. NIAID

6. Abdominal percussion for spleen (e.g., Castell’s sign) as a quick screen for splenomegaly before imaging. (Used clinically alongside palpation.) NIAID

Note: In ALPS, most decisive information comes from laboratory and flow cytometry rather than special bedside maneuvers; bedside checks help triage and monitor. ASH Publications

C) Laboratory & pathological tests (the core of diagnosis)

7. Complete blood count (CBC) with differential. Looks for anemia, thrombocytopenia, neutropenia, lymphocytosis. NCBI

8. Peripheral smear & reticulocyte count. Supports hemolysis (reticulocytosis, spherocytes) during autoimmune anemia. NCBI

9. Direct antiglobulin test (DAT/Coombs). Confirms autoimmune hemolysis. NCBI

10. Hemolysis panel (bilirubin, LDH, haptoglobin). Detects red cell destruction. NCBI

11. Serum immunoglobulins (often high IgG/IgA—hypergammaglobulinemia). New England Journal of Medicine

12. ALPS biomarkers: vitamin B12, IL-10, IL-18, soluble FAS ligand (sFASL)—often elevated in ALPS-FAS. NIAID+1

13. Flow cytometry for DNT cells (TCRαβ+ CD4− CD8−). An increased percentage is a hallmark. PMC

14. Genetic testing for TNFRSF6 (FAS)—sequencing and deletion/duplication analysis; if negative, test FASLG, CASP10, CASP8. NCBI

15. Somatic mutation testing (sorted T-cell subsets) if germline testing is unrevealing, to diagnose ALPS-sFAS. New England Journal of Medicine

16. FAS-mediated apoptosis assay (functional test): measures whether patient lymphocytes undergo apoptosis when FAS is triggered. NCBI

17. Autoantibody screens (e.g., ANA; disease-specific as indicated) to map other autoimmune targets. NCBI

18. Lymph node or bone marrow biopsy when needed to exclude lymphoma or assess unexplained cytopenias; pathology often shows polyclonal expansion, not malignancy. NCBI+1

19. Viral studies (EBV, CMV, HIV, etc.) when the presentation is atypical or severe—to rule out infections that can mimic or trigger flares. PMC

D) Electrodiagnostic tests

20. Not routinely indicated. ALPS is an immunologic (not neurologic or muscular) disorder, so EMG/NCS/EEG are not part of standard work-ups—unless symptoms specifically suggest a separate nerve or muscle problem. Diagnostic focus should remain on flow cytometry, apoptosis function tests, biomarkers, and genetics. ASH Publications+1

E) Imaging tests (ordered when needed)

• Abdominal ultrasound to size spleen/liver and avoid radiation, especially in children. CT/MRI (and occasionally PET-CT) are reserved for complex cases or when lymphoma is suspected. Imaging complements, but does not replace, the lab/genetic criteria. MedlinePlus+1

Non-pharmacological treatments (therapies & other supports)

Each item explains what it is, the purpose, and the mechanism in plain words.

1. Education & action plan.
   A simple written plan that tells the person and family what ALPS-FAS is, warning signs (like sudden pale skin or bleeding), and what to do during a fever or bleeding episode. Purpose: reduce delays in care. Mechanism: clear steps improve rapid response, reduce risk in emergencies. NCBI

2. Regular specialist follow-up.
   Care with immunology/hematology to track lymph node size, spleen size, blood counts, and side effects of therapy. Purpose: early detection of flares and lymphoma risk. Mechanism: scheduled monitoring and targeted tests guide timely treatment. NCBI

3. Vaccination optimization (non-live when immunosuppressed).
   Stay current on inactivated vaccines (influenza, pneumococcal, etc.). Avoid live vaccines while on significant immunosuppression. Purpose: prevent common infections. Mechanism: safe immunization builds protection without over-risk. NCBI

4. Infection-prevention habits.
   Hand hygiene, prompt care for fevers, dental care, and safe food/water practices. Purpose: cut infection risk during cytopenias or immunosuppression. Mechanism: lowers exposure to germs. NCBI

5. Post-splenectomy precautions (if ever performed).
   If a prior splenectomy exists, strict fever plan, emergency antibiotics access, and pneumococcal/meningococcal/HiB boosters. Purpose: reduce sepsis risk. Mechanism: compensates for loss of spleen’s filtering role. (Note: splenectomy is generally discouraged—see below.) PMC+1

6. Activity tailoring during flares.
   When platelets are very low, avoid contact sports and use protective strategies to prevent bleeds. Purpose: reduce trauma/bleeding. Mechanism: lowers injury risk while counts recover. (General supportive practice for cytopenias.)

7. Nutrition pattern for energy & immunity.
   Balanced meals with adequate protein, iron-rich foods, fruits/vegetables for micronutrients. Purpose: support blood cell building and recovery from anemia. Mechanism: supplies building blocks (iron, folate, B12) and antioxidants. (General supportive practice.)

8. Bone health program when using steroids.
   Calcium, vitamin D intake, weight-bearing exercise; baseline bone density if on long courses of steroids. Purpose: prevent bone thinning. Mechanism: counters steroid-related bone loss. (General guideline-based supportive care.)

9. Sun & skin protection.
   Some medicines increase sun sensitivity; also, skin bruising may be more visible during low platelets. Purpose: avoid sunburn and skin injury. Mechanism: barrier protection reduces damage. (General supportive practice.)

10. School/work accommodations.
    Notes for flexible attendance during flares and infection seasons. Purpose: maintain education/employment with safety. Mechanism: reduces exposure and stress.

11. Psychosocial support & counseling.
    Living with a rare disease is stressful. Purpose: reduce anxiety/depression, improve adherence. Mechanism: coping skills and peer support groups. (Primary Immune Deficiency community resources are helpful.) Primary Immune

12. Fever protocol at home.
    Thermometer use, what temperature triggers a call, and where to go. Purpose: earlier evaluation of serious bacterial infection. Mechanism: speeds antibiotics when needed (especially if asplenic). PMC

13. Bleeding precautions.
    Soft toothbrush, careful shaving, avoiding NSAIDs when platelets are low unless a doctor approves. Purpose: reduce mucosal bleeding. Mechanism: minimizes platelet function impairment and local trauma. (General hematology practice.)

14. Transfusion planning.
    If transfusions are needed during severe anemia or bleeding, use leukoreduced and irradiated products when appropriate. Purpose: reduce reactions. Mechanism: lowers alloimmunization risk. (General hematology practice.)

15. Monitoring for lymphoma signs.
    New B-symptoms (fever, night sweats, weight loss), rapidly growing nodes. Purpose: early detection. Mechanism: prompt imaging/biopsy if needed. NCBI

16. Drug interaction checks.
    Systematic review of medicines and herbs before starting sirolimus or MMF. Purpose: avoid harmful interactions. Mechanism: pharmacist review prevents toxicity. (General pharmacology guidance.)

17. Dental & ENT coordination.
    Large tonsils/nodes can affect airway/snoring. Purpose: safe anesthesia planning and dental/ENT care. Mechanism: anticipates bleeding/infection risks. (General supportive practice.)

18. Fertility/pregnancy planning (adolescents/young adults).
    Discuss medicine safety in pregnancy and contraception while on teratogens. Purpose: protect parent and baby. Mechanism: pre-conception counseling reduces risk. (General immunology/hematology practice.)

19. Travel planning.
    Carry summary letter, vaccines updated, access to antibiotics (especially if asplenic), and medical insurance. Purpose: reduce emergencies abroad. Mechanism: preparedness in higher-risk regions. PMC

20. Shared-care coordination.
    Clear communication between local doctors and reference center. Purpose: seamless care. Mechanism: unified plan reduces mixed messages and errors. NCBI

---

Drug treatments

*Doses vary by age/weight and by clinician judgment. Always individualize with a specialist.

1. Sirolimus (rapamycin) — mTOR inhibitor.
   Dose: often 1–2 mg orally daily (children weight-based); levels monitored. Timing: maintenance; weeks to see full effect. Purpose: first-line steroid-sparing therapy for recurrent cytopenias and lymphoproliferation. Mechanism: calms overactive T-cell responses and reduces double-negative T cells. Side effects: mouth sores, high lipids, infections, delayed wound healing; monitor drug level and kidneys/lipids. Robust ALPS evidence. PMC+1

2. Mycophenolate mofetil (MMF) — antimetabolite immunosuppressant.
   Dose: e.g., 600–1,000 mg twice daily. Timing: maintenance. Purpose: steroid-sparing for autoimmune cytopenias if sirolimus is not tolerated/available. Mechanism: blocks lymphocyte purine synthesis to reduce autoimmunity. Side effects: GI upset, infections, low white cells; avoid in pregnancy. PMC

3. Corticosteroids (prednisone; dexamethasone pulses) — glucocorticoids.
   Dose: varies (e.g., prednisone 1–2 mg/kg/day short term). Timing: acute flares. Purpose: rapid control of autoimmune hemolysis or thrombocytopenia. Mechanism: broad immunosuppression reduces auto-antibody and inflammation. Side effects: mood changes, high sugar, hypertension, bone loss, infection; minimize long-term use. PMC

4. Rituximab — anti-CD20 monoclonal antibody.
   Dose: e.g., 375 mg/m² weekly × 1–4. Timing: rescue for severe refractory cytopenias. Purpose: deplete B cells to reduce autoantibodies. Mechanism: targets CD20 on B cells. Side effects: infusion reactions, prolonged low immunoglobulins, infections; vaccine response impaired. Use cautiously; some experts discourage routine use in ALPS compared with sirolimus. PMC+1

5. Intravenous Immunoglobulin (IVIG) — pooled IgG.
   Dose: commonly 1–2 g/kg divided over 1–2 days for immune thrombocytopenia or hemolysis. Timing: acute episodes or bridging. Purpose: transiently raises platelets/blocks hemolysis. Mechanism: Fc-receptor blockade and immune modulation. Side effects: headache, aseptic meningitis, thrombosis risk; effect is temporary. Frontiers

6. Everolimus — mTOR inhibitor (related to sirolimus).
   Dose: individualized with trough levels. Timing: alternative when sirolimus unavailable/not tolerated. Purpose/Mechanism: similar to sirolimus. Side effects: similar class effects. Evidence smaller than sirolimus. PMC

7. Azathioprine — antimetabolite.
   Dose: often 1–2 mg/kg/day. Timing: maintenance (less favored now). Purpose: steroid-sparing in cytopenias. Mechanism: inhibits lymphocyte proliferation. Side effects: marrow suppression, liver injury, infection; TPMT testing helpful. (Older option; use has declined with mTOR data.) PMC

8. Cyclosporine — calcineurin inhibitor.
   Dose: e.g., 3–5 mg/kg/day in divided doses with level monitoring. Timing: second/third-line. Purpose: refractory cytopenias. Mechanism: blocks T-cell activation (IL-2). Side effects: kidney toxicity, hypertension, gum changes, tremor, infections. PMC

9. Tacrolimus — calcineurin inhibitor.
   Dose: individualized with trough levels. Timing/Purpose/Mechanism: similar to cyclosporine. Side effects: kidney toxicity, diabetes risk, tremor. (Selected cases.) PMC

10. Cyclophosphamide (short course) — alkylator.
    Dose: specialist-directed. Timing: rescue in life-threatening autoimmunity when others fail. Purpose: strong immunosuppression. Mechanism: kills dividing lymphocytes. Side effects: marrow suppression, infertility risk, infections; used rarely now. PMC

11. Methotrexate (low-dose) — antimetabolite.
    Dose: weekly low dose with folic acid. Purpose: adjunct steroid-sparing in autoimmune inflammation. Mechanism: anti-folate; immunomodulation. Side effects: liver toxicity, marrow suppression, mucositis; avoid in pregnancy. (Selected cases.) PMC

12. Eltrombopag — TPO-receptor agonist.
    Dose: weight- and liver-adjusted; taken daily. Purpose: raise platelets in chronic immune thrombocytopenia when autoimmunity persists. Mechanism: stimulates platelet production. Side effects: liver enzyme rise, clot risk; requires monitoring. (Evidence mainly extrapolated from ITP; consider specialist input.) Frontiers

13. Romiplostim — TPO-receptor agonist (injection).
    Dose: weekly subcutaneous dose adjusted to platelet response. Purpose/Mechanism/Side effects: similar to eltrombopag. (Case-by-case use.) Frontiers

14. G-CSF (filgrastim) — hematopoietic growth factor.
    Dose: intermittent injections when neutropenia is severe with infections. Purpose: increase neutrophils quickly. Mechanism: stimulates marrow neutrophil production. Side effects: bone pain; rarely spleen issues—monitor size. (Supportive use.) PMC

15. TMP-SMX (infection prophylaxis in selected patients) — antibiotic.
    Dose: low-dose prophylaxis schedule when immunosuppressed or asplenic (doctor-directed). Purpose: prevent serious bacterial infections and Pneumocystis. Mechanism: suppresses targeted pathogens. Side effects: rash, cytopenias; check allergies and counts. PMC

16. Penicillin/Amoxicillin prophylaxis (asplenia) — antibiotic.
    Dose: daily dosing post-splenectomy (if present). Purpose: prevent sepsis. Mechanism: suppresses encapsulated bacteria. Side effects: allergy, GI upset. (Only if spleen removed; again, splenectomy is discouraged.) PMC+1

17. Antifolate support: folic acid — vitamin.
    Dose: daily 1 mg (varies). Purpose: support red cell production during hemolysis. Mechanism: replenishes folate used in RBC turnover. Side effects: very safe; confirm B12 status. (Supportive hematology practice.)

18. Proton-pump inhibitor (with steroid bursts) — gastric protection.
    Dose: daily while on high-dose steroids. Purpose: reduce stomach ulcer risk. Mechanism: suppresses acid. Side effects: headache, diarrhea; keep duration short. (General practice.)

19. Acetaminophen for pain/fever — analgesic/antipyretic.
    Dose: per weight/label. Purpose: symptom relief without platelet effects. Mechanism: central COX action. Side effects: liver risk at high doses; avoid NSAIDs when platelets are low unless approved. (General practice.)

20. Hematopoietic Stem Cell Transplant (HSCT) conditioning meds — transplant regimen.
    Dose/Timing: specialized protocol. Purpose: curative option for a small subset with severe, refractory disease or lymphoma. Mechanism: replaces the defective immune system. Side effects: significant risks (infections, graft-versus-host disease). Used rarely and only in expert centers. PMC+1

---

Dietary molecular supplements

These can support general health, bone protection during steroids, and red cell recovery. Evidence is supportive/adjunctive—not disease-curative.

1. Vitamin D3.
   Dose: commonly 800–2,000 IU/day (adjust to level). Function: bone and immune support, especially with steroid use. Mechanism: vitamin D pathways help bone mineralization and modulate immune responses. (Supportive practice with steroids.) PMC

2. Calcium.
   Dose: to reach ~1,000–1,200 mg/day from diet + supplements. Function: maintain bone strength during steroid exposure. Mechanism: provides mineral substrate. (General guideline.) PMC

3. Folic acid.
   Dose: ~1 mg/day. Function: supports RBC production in hemolysis. Mechanism: DNA synthesis for erythropoiesis. (Hematology practice.)

4. Vitamin B12 (if low).
   Dose: per deficiency protocol. Function: corrects macrocytosis and anemia if deficient. Mechanism: cofactor for DNA synthesis. (Check levels.)

5. Iron (if iron-deficient).
   Dose: per labs; oral iron typical. Function: rebuilds hemoglobin. Mechanism: supplies iron for RBCs. (Treat only if deficient.)

6. Omega-3 fatty acids (fish oil).
   Dose: common 1–2 g/day EPA/DHA. Function: anti-inflammatory support. Mechanism: resolves inflammatory mediators; caution with bleeding risk if platelets very low. (Adjunct only.)

7. Multivitamin with trace minerals.
   Dose: daily. Function: covers gaps during illness and poor appetite. Mechanism: broad micronutrient repletion.

8. Probiotics (discuss first).
   Dose: product-specific. Function: GI well-being during antibiotics. Mechanism: supports gut flora; avoid if severely immunocompromised. (Caution.)

9. Curcumin (turmeric extract).
   Dose: product-specific. Function: mild anti-inflammatory adjunct. Mechanism: NF-κB modulation; potential interactions with anticoagulants. (Adjunct; evidence modest.)

10. Protein-rich nutrition (whey or plant protein).
    Dose: to meet daily protein goals. Function: supports marrow recovery and healing. Mechanism: amino acids for tissue building.

These supplements don’t replace disease-directed therapy. Always check interactions (e.g., with sirolimus or MMF). PMC

---

Immunity-booster / regenerative / stem-cell–oriented” therapies

1. Sirolimus (mTOR inhibitor).
   Dose: individualized; daily oral. Function: re-balances immune system; reduces abnormal T-cell signals. Mechanism: mTOR pathway suppression; lowers DNT cells. PMC

2. Everolimus (mTOR inhibitor).
   Dose: individualized. Function/Mechanism: like sirolimus; alternative agent. PMC

3. IVIG (passive immunity).
   Dose: periodic infusions. Function: provides concentrated antibodies; useful for acute cytopenias or low IgG. Mechanism: immune modulation and pathogen neutralization. Frontiers

4. G-CSF (filgrastim).
   Dose: intermittent injections. Function: boosts neutrophils during severe neutropenia with infections. Mechanism: stimulates marrow granulopoiesis. PMC

5. Eltrombopag/Romiplostim (TPO agonists).
   Dose: as directed. Function: regenerate platelet counts in chronic immune thrombocytopenia. Mechanism: stimulates megakaryocytes. Frontiers

6. Hematopoietic Stem Cell Transplant (HSCT).
   Dose: transplant conditioning + donor stem cells. Function: potential cure by replacing defective immune system. Mechanism: engrafted donor immunity restores apoptosis pathways. (Reserved for severe refractory disease in expert centers.) PMC+1

---

Procedures / surgeries

1. HSCT (bone-marrow/hematopoietic stem cell transplantation).
   Procedure: chemo ± radiation conditioning, donor stem cell infusion, ICU-level monitoring. Why: potential curative option for the few with life-threatening, treatment-refractory disease or lymphoma. Note: carries significant risks; center expertise required. PMC+1

2. Splenectomy (generally discouraged now).
   Procedure: surgical spleen removal. Why: historically used for chronic low platelets; today avoided because it raises life-long sepsis risk and often doesn’t give durable benefit in ALPS. Consider only in exceptional cases with strict prophylaxis. PMC+1

3. Lymph node excisional biopsy (diagnostic).
   Procedure: remove a node to rule out lymphoma and confirm benign lymphoproliferation. Why: clarifies diagnosis if nodes change rapidly or have “red flags.” NCBI

4. Bone marrow biopsy (diagnostic).
   Procedure: marrow sampling from hip bone. Why: evaluate unexplained cytopenias, exclude malignancy or other marrow disorders. NCBI

5. Central venous port placement (supportive).
   Procedure: small implantable IV port. Why: in patients needing frequent infusions (IVIG, transfusions), to reduce repeated needle sticks. (Supportive practice.)

---

Prevention tips

1. Keep scheduled specialist visits and blood tests. NCBI

2. Vaccinate appropriately (avoid live vaccines while on strong immunosuppression). NCBI

3. Avoid splenectomy whenever possible; if already asplenic, follow strict fever plan and antibiotic prophylaxis. PMC+1

4. Prompt fever care: seek medical help the same day for fever ≥38.5 °C, especially if counts are low or asplenic. PMC

5. Hand hygiene and infection-safe habits at home/school/work.

6. Protect bones if you need steroid bursts (vitamin D, calcium, exercise). PMC

7. Check drug interactions with sirolimus/MMF before starting any new medicine or supplement. PMC

8. Avoid NSAIDs when platelets are low unless your doctor approves.

9. Report new “B-symptoms” (night sweats, weight loss, persistent fever) or rapidly growing nodes. NCBI

10. Carry a medical summary (diagnosis, medicines, emergency plan), especially when traveling. PMC

---

When to see a doctor urgently

• Fever 38.5 °C (101.3 °F) or higher, chills, or feeling very unwell—especially if you are on immunosuppression or do not have a spleen. PMC

• Bleeding or easy bruising, black stools, blood in urine, nosebleeds that don’t stop (possible low platelets).

• Severe fatigue, paleness, shortness of breath (possible anemia).

• New, fast-growing lymph nodes, night sweats, or unexplained weight loss (evaluate for lymphoma). NCBI

• Severe abdominal pain or sudden spleen enlargement.

• Any new severe medication side effect (mouth ulcers on sirolimus, high sugars on steroids, infections). PMC

---

What to eat and what to avoid

1. Eat: balanced meals with lean protein (fish, eggs, beans) to support blood cell production.

2. Eat: iron-rich foods (lean red meat, legumes, spinach) if iron-deficient per labs; add vitamin-C foods to improve iron absorption.

3. Eat: folate and B12 sources (leafy greens, fortified cereals; dairy/eggs/meat for B12) to support red blood cells.

4. Eat: fruits and vegetables daily for antioxidants and micronutrients.

5. Drink: enough fluids; limit sugary drinks.

6. Include: calcium and vitamin D foods (dairy or fortified alternatives), especially with steroid exposure. PMC

7. Avoid or limit: alcohol (can worsen marrow suppression and interact with medicines).

8. Avoid: raw/undercooked meats and unpasteurized products if you are significantly immunosuppressed.

9. Be cautious with herbal supplements (e.g., St. John’s wort can interact with sirolimus); ask your clinician first. PMC

10. Avoid NSAIDs like ibuprofen when platelets are low unless a clinician says it’s safe.

---

Frequently Asked Questions

1. Is ALPS-FAS the same as FAS deficiency?
   Yes. “FAS deficiency” refers to ALPS caused by disease-causing variants in the FAS (CD95) gene. NCBI

2. Why do lymph nodes and spleen get big?
   Faulty Fas “self-destruct” signals let immune cells live too long and pile up. NCBI

3. What are double-negative T cells?
   They are T cells that have the αβ T-cell receptor but lack CD4 and CD8. High levels in blood or lymphoid tissue are a signature marker for ALPS-FAS. ASH Publications

4. What problems happen most often?
   Swollen nodes/spleen and autoimmune cytopenias (low red cells, platelets, sometimes neutrophils). NCBI

5. Is there a cancer risk?
   Yes—higher risk of lymphoma compared with the general population; regular follow-up is important. NCBI

6. What is the main modern treatment?
   Sirolimus (mTOR inhibitor) is now a leading steroid-sparing therapy with strong evidence in ALPS. PMC+1

7. Are steroids still used?
   Yes, but mostly for short bursts during flares because of side effects with long use. PMC

8. Is splenectomy recommended?
   Usually no. It increases life-long infection risk and often doesn’t give lasting benefit in ALPS. PMC+1

9. Can ALPS be cured without transplant?
   Most people are managed medically; HSCT can be curative but is reserved for severe, refractory cases due to risks. PMC

10. Can adults be diagnosed, or just children?
    Both. Many are diagnosed in childhood, but adults can be diagnosed later based on history, labs, and genetics. NCBI

11. Do all FAS mutations cause the same disease severity?
    No. Some people with a mutation have milder disease (variable penetrance). Somatic (mosaic) FAS variants can also cause ALPS features. JACI

12. What labs are followed over time?
    Blood counts, DNT cells (in some centers), liver/kidney tests, lipids (with sirolimus), and drug levels for sirolimus/everolimus. PMC

13. Can vaccines be taken?
    Inactivated vaccines are encouraged; live vaccines are avoided during significant immunosuppression. NCBI

14. Are there ALPS-like conditions?
    Yes—other gene defects can mimic ALPS and must be considered and tested when the picture isn’t classic. JACI

15. Where can I learn more?
    GeneReviews (ALPS), NORD, and reputable immunology centers have detailed overviews for families and clinicians. NCBI+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 29, 2025.